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Abstract
We aimed to review the literature on interventions for treating Common Mental Disorders (CMD) in people
with Tuberculosis (TB). We followed PRISMA guidelines and the protocol was registered at PROSPERO. The
electronic databases (PsycInfo, CINAHL, Medline, Google Scholar, Embase) were searched from 1982 to 2020.
349 relevant records were screened, with 26 examined at full text. 13 studies were included totalling 4326
participants. A meta-analysis was not possible due to nature of data, thus descriptive synthesis was conducted.
Eleven studies evaluated psychosocial interventions, which significantly improved adherence or cure rates from
TB, anxiety and depression. The elements of effective psychosocial interventions included; combating stigma,
socioeconomic disadvantage, managing associated guilt and fear of contagion, and explanatory models of illness in
local population. Two articles evaluated pharmacological interventions (antidepressants and Vitamin D). This is
the first systematic review of interventions to treat CMD in TB. The studies were mostly low quality and mental
health outcomes were not adequately described. However, this review suggests that it is feasible to develop and
test interventions for improving mental health outcomes and enhancing treatment adherence in TB.
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Introduction
Tuberculosis (TB) is one of the top 10 causes of death and
the leading cause from a single infectious agent (above
HIV/AIDS).1 Common mental disorders (CMD), an
umbrella term for depression (and subthreshold disor-
ders) and anxiety disorders, are major multimorbidities
associated with TB.2,3 Common Mental Disorders
include the following psychiatric disorders: depression,
generalised anxiety disorder (GAD), panic disorder, pho-
bias, social anxiety disorder, obsessive-compulsive dis-
order (OCD) and post-traumatic stress disorder (PTSD).4
Depression is a common condition among the
CMD studied in relation to TB and Multi Drug Resis-
tant TB (MDR-TB).5 The prevalence of depression in
patients receiving treatment for TB ranges from
11.3% to 80.2%, with a mean weighted prevalence
of 48.9%.5 A recent scoping review found varying
prevalence rates of anxiety amongst Tuberculosis
patients, ranging from 2% to 27%.6
The relationship between depression and TB is
bidirectional. Depression is associated with a range
of adverse outcomes in TB such as poor functional
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impairment, poor adherence to medication and self-
care regimens, increased medical symptom burden
and increased mortality.7,8 Depression may also
increase risk of TB reactivation, antibiotic drug resis-
tance, contribute to disease progression, and/or inhibit
the physiological response to anti-tuberculosis treat-
ment (ATT). Conversely, TB may precipitate depres-
sion, as a result of altered inflammatory responses
and/or dysregulation of the hypothalamic-pituitary-
adrenal axis, or the side effects of ATT.9 This results
in worse prognoses for TB, treatment with drugs that
have significant neuropsychiatric side effects,
enhanced stigma and social isolation. These factors
then lead to further depression and anxiety.9,10
Common mental disorders, especially depression
may be linked to non-adherence to ATT, which is a
major barrier in Tuberculosis control.11 Untreated
depression at baseline is independently associated
with greater disability, poorer quality of life,12,13 TB
treatment default12 and negative TB treatment out-
comes.14 Poor adherence with TB treatment leads to
multi drug resistant TB (MDR-TB)5 MDR-TB is
declared as a health security threat by WHO.1
In view of the high prevalence of CMD in TB and their
deleterious effects on TB outcomes, the interventions to
treat CMD in TB will have major public health advan-
tages. At present the interventions to treat CMD in asso-
ciation with TB have not been systematically reviewed.
We therefore aimed to review the literature on inter-
ventions used for treating CMD in people with TB. We
included both pharmacological and non-pharmacological
interventions. The non-pharmacological interventions
include any psychosocial interventions that are
focused on psychological or social factors, including,
but not limited to, individual, family, or group psycho-
logical therapies, education, or training.15 We will
refer to non-pharmacological interventions as psycho-
social interventions in the rest of article.
Our primary aim was to identify the interventions
for treating CMD and how these can be implemented
in TB control programmes. Specifically, we aimed to
answer following questions:
 What interventions have been used for treating
CMD in people with TB?
 What is the evidence of effectiveness of psy-
chological, pharmacological and psychosocial
interventions for treating CMD in TB?
 What is the methodological quality of the evi-
dence that is available for treating CMD,
particularly depression and how can this can
be scaled up?
Materials and methods
We followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
statement guidelines.16 A protocol defining the key
methodological parameters was developed prior to the
literature search and was registered at the Interna-
tional Prospective Register of Systematic Reviews
(PROSPERO) (https://www.crd.york.ac.uk/PROS
PERO/display_record.php?RecordID¼176124). The
protocol was revised (April, 2020 and July 2020).
These were to expand the search date parameters, and
to include all common mental disorders.
Search strategy
The following electronic databases and platforms were
searched from 1982 to 2020; PsycInfo, CINAHL, Med-
line, Embase, Pubmed and Google Scholar. Tubercu-
losis is mostly prevalent in low and middle income
countries (LAMI), and therefore the search strategy
was adapted to be reflective of this. Most journals from
LAMI countries are not indexed in the mainstream
databases; therefore, Google Scholar was used to iden-
tify relevant studies. We have used this search strategy
previously to identify literature from LMIC.17 WHO
estimates were used to determine the 20 countries
where TB prevalence is highest. Each of these coun-
tries were added to the existing search strategy, and the
first 40 results from Goggle Scholar were examined for
relevant articles. We also searched the bibliography of
included studies and four relevant reviews on epide-
miology of depression in people with TB.14,18,19
The following search terms were used: Depression
(all variants) mood disorder* (all variants) neurosis
(all variants) anxiety (all variants) common mental
health problem, Tuberculosis, TB, multi-drug resistant
tuberculosis, MDR-TB, anti-tuberculosis treatment,
ATT, rifampicin, ethambutol, INH streptomycin iso-
niazid. The following were used to search for psy-
chosocial interventions; psychological treatment,
psychotherapy, cognitive behaviour* therapy (all
variants) counselling, behavioural activation (all
variants) OR interpersonal therapy OR psychody-
namic psychotherapy OR psychosocial treatment*,
befriending, non-pharmacological, self-help, counsel-
ling, interpersonal psychotherapy. Pharmacological
interventions were searched for using pharmacological
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treatment* OR *drug treatment* or *Antidepressants*
(All variants). Truncations and related terms were used
as appropriate based on individual database procedures
(please see Online Appendix for search strategy).
We included all studies that reported interventions
for CMD. For the purpose of this review we adopted
study defined criteria for diagnosis of CMD. Further-
more, the study defined diagnosis of TB or MDR-TB
was used. Interventions for MDR-TB were also
included. Studies describing patients above 5 years
old were included.
We employed a broad definition of psychosocial
interventions. This included studies that reported any
interventions with psychological or psychosocial ele-
ments addressing the psychological consequences of
suffering from TB using a broad approach. These
approaches could be based on a defined psychological
approach such as Cognitive Behavioural Therapy
(CBT) (a talking therapy that helps you manage dif-
ficulties by changing the way you think), counselling,
interpersonal therapy (therapy focusing on your rela-
tionships with people) and behavioural activation
(increasing pleasurable activity) or any combination
of these. Pharmacological interventions included any
pharmacological interventions used for treating anxi-
ety or depression. Articles that aimed to prevent rather
than treat anxiety and depression reported in TB due
to Bovine TB were excluded.
Data extraction and collection
After completing the search process and screening for
relevant abstracts, examination of full text articles for
inclusion and data extraction was completed by two
reviewers (SF & RC) independently, as outlined in the
protocol.20 Data extraction began on 14/04/2020. Dis-
agreements regarding study selection or data extraction
were resolved by consensus or by a third reviewer (JT)
where needed. References of articles were also manu-
ally searched to identify additional relevant articles.
A data extraction sheet was developed based on the
pre-specified outcomes. Relevant data was extracted
by one reviewer (JT) and cross checked by another
reviewer (RC). Studies were categorised in terms of;
objectives of the study, methodology, (quantitative or
qualitative), design, setting, key findings and interven-
tions (pharmacological and non-pharmacological).
Risk of bias (quality assessment)
The quality of the studies was assessed independently
by two reviewers using appropriate checklists. The
intervention studies were assessed using Cochrane
collaboration tool and for observational studies and
we planned to use the Newcastle-Ottawa tool for non-
intervention studies. The quality of intervention stud-
ies using RCT design was assessed based on the seven
principles of risk of bias assessment tool and were
categorised as having; low, high and unclear risk of
bias for each item in the tool.
Results
The electronic searches returned 349 relevant abstracts
and titles. These included 186 records from electronic
searches of the scientific literature databases (PubMed,
Psychinfo, Medline & CINHAL) and 200 from the
Google Scholar search. We screened the titles and
abstracts and excluded the studies which were not
directly relevant to the objectives of the review. After
screening these titles and abstracts and removal of
duplications we decided to examine 26 full text papers.
Finally, we included 13 papers in the review.
Out of the total included studies, four21–24 were
identified through Google search and the remaining
were identified through the scientific databases. The
details of search yield and reasons for excluding the
full text articles are provided in Figure 1.
Figure 1 denotes the PRISMA diagram which
shows search process that was carried out in selecting
texts for final review. 12 articles were excluded at full
text phase, with reasons for exclusions are given,
leaving 13 studies for final inclusion.
Characteristics of included studies
Thirteen studies met the inclusion criteria; 2 used
pharmacological interventions and 11 of these studies
focussed on different psychosocial interventions.
Eleven studies were published from LMIC countries;
Peru (3), India (2), Nepal (2), East Kazakhstan (1),
Pakistan (1), Indonesia (1) and Ethiopia (1). Two
studies were published from China which is now clas-
sified as upper middle income country.
Total numbers of participants in all studies were
4326. This comprised of TB (n¼ 1005) and MDR-TB
(n ¼ 1572) patients. The studies also include 1742
participants who were household contacts with no
TB diagnosis25 and nurses (n ¼ 7).22
Eleven studies described psychosocial interven-
tions. These included pharmacists led patient educa-
tion intervention26 psychological counselling and
health education27,28 behaviour modification using
psychotherapy,29 and psychological therapy to treat
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depression.28 Li and colleagues30 describe a multifa-
ceted intervention including health education, psy-
chotherapy and psychoeducational workshops. Four
studies described psychosocial interventions for
MDR-TB.21,23–25 One study describes the emotional
support given by nurses to MDR-TB patients.22 These
studies used widely different methodologies from
qualitative studies describing developing the inter-
vention development, process to RCTs evaluating
these interventions. Two studies evaluated pharmaco-
logical interventions.31,32
Table 1 describes the characteristics of the final
included studies in this review, including; author,
year, country, setting, population, method, design and
sample characteristics.
Characteristics of interventions
Different psychosocial interventions were used for
improving treatment adherence with ATT and mental
health outcomes. Three studies23,24,26 used group
therapy approaches, four studies22,29,28,33 used indi-
vidual therapy and four papers21,25,27–30 described
both individual and group approach in providing psy-
chosocial interventions. The number of individual and
group sessions differed widely between studies but
mostly consisted of 8–10 sessions.
The interventions were provided by nurses,22,24,25,28
a psychiatrist and/or nurses,23 pharmacists,26 lay
health workers,27 trained health professionals,33
combination of health workers and therapists30 and
psychologists.21,29
Five studies provided a theoretical orientation of
the intervention used in treatment. Walker and col-
leagues27 used a Healthy Activity Program (HAP)
approach which is based on behavioural activation
(BA) therapy. Tola et al.33 described a therapy based
on health belief models of the local population about
anxiety and depression. Sari et al.28 used Acceptance
and Commitment Therapy (ACT),34 which was also
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Figure 1. PRISMA diagram.
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based on the Health Belief Model. ACT focuses on
accepting difficult feelings and emotions to enhance
psychological flexibility.34 Janmeja and colleagues29
used a psychological intervention based on behaviour
therapy and Motivational Enhancement Therapy
(MET) of Prochaska and DiClemenete.35 Li et al.30
used Morita therapy,36 a kind of cognitive beha-
vioural therapy, which focused on shifting the atten-
tion away from the disease to their daily life and
external environment.
Two pharmacological intervention studies used
Imipramine 75 mg32 and Vitamin D supplementa-
tion31 for treatment of depressive symptoms in people
with TB.
Table 2 describes and summarises the character-
istics of the psychosocial interventions that were
used to treat psychological problems in people with
TB and MDR-TB. Individual therapy, group therapy
and a combination of the two approaches are
described here.
The treatment outcomes
We planned a meta-analysis of mental health out-
comes for CMD. The studies were conducted in num-
ber of different populations, settings and used
different interventions and diverse methodologies.
Due to the diverse methodologies, study designs and
Table 1. Characteristics of included studies.
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India Randomised Control Trial Patients screened but
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Intervention N ¼ 30
Control N ¼ 29
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Rocha et al.,
2011
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inconsistent, and in some cases poor, reporting of
mental health outcomes, it was inappropriate to pool
the data to produce a statistical summary. We there-
fore describe the main findings and produce a narra-
tive summary of results.
Kaukab et al.26 used Becks Depression Inventory
to measure the outcome of a pharmacy-based
intervention. Depression improved significantly at
10 months’ post intervention compared to baseline
(moderate depression baseline 54.26% versus 11.43%
post intervention, and severe depression 37.14% at
baseline versus zero at the end of intervention).
In a prospective controlled trial, Janmeja et al.29
evaluated the role psychotherapy (eight sessions) ver-
sus treatment as usual in India. Hamilton Rating Scale
for depression (HSRD) was used pre-intervention.
Treatment adherence and cure rates for TB improved
in the intervention group compared to the control;
(83% versus 47% and 72% versus 42% respectively).
The psychotherapy resulted in improvement in mea-
sures such as motivation to take drugs and disease
related anxiety but no specific improvement in
depression was reported in the study
A cluster randomised control by Tola et al.33 eval-
uated the effectiveness of a psychological interven-
tion that had two components; anxiety and depression
counselling and patient education. The study reported
a significant improvement in treatment adherence
(treatment non-adherence in the intervention group
[9.5%] versus 25.4% in control group; p < 0.001).
Mental health outcomes were measured at baseline
using Kessler–10 (K-10) item questionnaire. The
intervention resulted in significant improvement in
psychological distress (mean score on Kessler-10
item scale 14 [SD +5] in the intervention group
versus 19 [+8.1] among control group at the end
of follow up period). The intervention groups also
had significant improvement in the knowledge about
the disease, perceived susceptibility, and perceived
self-efficacy.
Four sessions of Acceptance and Commitment
Therapy (ACT), based on the Health Belief Model
was used by Sari et al.28 ACT resulted in significant
improvement in depression as measured by Beck
Depression Inventory (BDI) (mean BDI in interven-
tion group 5.96 SD 1.45 compared to the mean BDI of
7.86 SD 3.05 in control group; P > .001).28
Walker et al.27 described a feasibility study of a
stepped care approach for treatment of anxiety and
depression in TB. Patients were screened for depres-
sion and anxiety (Hopkins Symptom Checklist,
HSCL) and low social support (using the Multidimen-
sional Scale of Perceived Support, MSPSS) monthly
in TB control programme. Those who screened posi-
tive on either tool (anxiety 17, depression 24 on
HSCL or 3 on MSPSS) received Health Activity
Programme (HAP) intervention (brief counselling
based on behavioural activation theory). In total, 29
participants were referred for counselling. The
patients who completed HAP counselling had a mean
reduction in scores on both depression tools (7.9
points on HSCL Depression, 2.7 points on PHQ-9).
Baral et al.24 used mixed methods, comprising a
formative qualitative study and a pilot intervention.
The pilot intervention study compared three groups;
‘counselling’, ‘combined counselling and financial
support’ and ‘care as usual’. Qualitative interviews
revealed participants felt their negative thoughts
decreased, and self-esteem increased. Counselling
alone and combined counselling and financial support
were valued by patients. The following cure rates
from TB were found; supported group counselling
(85%), support group counselling & financial support
(76%) and no support (54%). No specific mental
health outcomes were reported by authors; however
participants in both supported groups reported
improved understanding of TB and were able to solve
many problems related to its treatment.
Kaliakbarova et al.21 reported a qualitative pilot
study of a psychosocial support programme (PSSG)
intervention. PSSG was implemented for 226 patients
considered to be of high risk of MDR-TB treatment
default. They found that prior to the start of the pro-
gramme, 44 (23%) of 190 patients had interrupted TB
treatment at least once. After the PSSG, only one
patient (0.5%) had interrupted treatment only once.
Half of participants in the study (n ¼ 95) considered
that the psychological support provided by the pro-
gramme helped them to recover from the disease.
Rocha et al.25 evaluated a ‘socioeconomic support
intervention’ in a mixed method study. Baseline
depression scores were measured using the Beck
Depression Inventory. Patients and household con-
tacts had high rates of depression at baseline; 40%
of TB patients had any depression and 12% had severe
depression. They found that the intervention resulted
in successful TB treatment completion, better testing
for HIV (increase from 31% to 97%) and completion
of preventative therapy (from 27% to 87%). Depres-
sion scores were not given post intervention.
Chalco et al.22 explored the forms and means of
emotional support that nurses could provide to
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patients living with MDR-TB in Peru using ethno-
graphic and qualitative methods. Theme and content
analyses of data revealed 10 issues related to MDR-
TB care mostly related to implementing psychosocial
interventions (see below). The study did not report
specific mental health outcomes.
Acha et al.23 found that the psychosocial groups led
by teams of psychiatrists and nurses helped patients
with MDR-TB to cope with TB associated stigma as
they experienced social rejection and discrimination
from family members. The study did not report spe-
cific mental health outcomes but provides qualitative
data from the support groups, on therapeutic pro-
cesses to overcome depression and suicidal tenden-
cies. One powerful therapeutic effect of the group
was the inspiration of hope in participants including
a sense of belonging and cohesion. Suicide featured
frequently in discussions such as
All of us go through that (suicidal ideation); that’s nor-
mal. The beginning of treatment is so hard, but it gets
easier. I thought about killing myself many times. The
side effects were so bad; – But little by little, things got
better. We have to be strong. We can’t give up. The most
important thing to know is that you’re not alone. We’re
all in this together.23
Li et al.30 used the Zung self-rating Anxiety Scale
(SAS) and the Zung self-rating Depression Scale to
measure the outcome of a psychosocial intervention
to improve anxiety and depression among elderly TB
patients. This was the only study that looked specifi-
cally at the elderly TB population. At 6 months follow
up, significant improvement was found both for anxi-
ety and depression in the intervention group com-
pared to the control group.
Pharmacological treatments
Meghnani et al.32 compared Imipramine (25 mg) ver-
sus placebo. Significantly higher number of patients
improved on imipramine versus control group (86.7%
versus 48.3% in the control group; P < 0.01) using a
cut-off point of 13 on HDRS as criteria for remission
from depression.
In a pilot RCT, Zhang et al.31 used vitamin D in
120 patients (56 in vitamin D group versus 64 control)
presenting with pulmonary TB and meeting the DSM-
IV criteria for depression. Change in scores of depres-
sive symptoms was measured with the Chinese
version of the Beck Depression Inventory (BDI).
After 8-week treatment, although the BDI scores in
both the control and intervention decreased signifi-
cantly from baseline, the mean BDI scores were not
significantly different between intervention (16.6 +
9.4) and the control group (16.9 + 8.3); P ¼ 0.38.
Quality assessment of included studies
Seven studies used experimental designs to evaluate
the interventions but most provided little details on
the quality criteria for Cochrane tool for assessment of
RCTs. One study26 was described by authors as RCT
and another was described as quasi experimental.28
Both studies did not provide any details relevant to
quality criteria for RCT, so the Cochrane tool could
not be applied to these studies. The quality assessment
of remaining five studies is provided in Figure 2.
Only one study31 had a low risk of bias score on all
the items on Cochrane tool for the assessment of inter-
vention studies, the rest were classified as having high
risk of bias.
Figure 2. Risk of bias assessment.
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Figure 2 denotes the results of the quality assess-
ment that was carried out by the reviewers. This figure
demonstrates that only one figure scored as low risk
of bias, with the other studies scoring high.
Six studies used observational designs and were
suitable for quality assessment using the tool pro-
posed in the protocol. Two studies22,23 did not use
appropriate study designs, and did not provide rele-
vant information for using the Newcastle-Ottawa
Quality Assessment Scale (NOQAS) that we pro-
posed in the protocol for observational studies.
The NOQAS provides 1–3 stars for each item such
as such as description of cohorts, outcome and ascer-
tainment of exposure, and we converted this to a
numerical score. The maximum score for a study is
10. Out of six studies, four studies used a validated
measurement tool to measure mental health out-
comes.25–28 One study (Sari et al.)28 scored 7 out of
a possible 10 stars, two studies scored 6,26,27 one
study scored 525 one study scored 424 and one study21
scored 2 out of a possible 10.
Discussion
This is the first systematic review of interventions to
treat common mental disorders in people with TB and
MDR-TB. We used a broad inclusion criterion to
examine all possible designs and interventions to
inform research and clinical practice. Since a meta-
analysis was not possible, it is not possible to provide
quantitative outcomes for the interventions. The main
findings are (i) All studies reported improvement in
adherence or cure rates from TB/MDR-TB, either in
comparison to a control group or in comparison to
pre-intervention rates with the use psychosocial inter-
ventions, (ii) specific outcomes related to anxiety and
depression were not adequately described but most
studies reported improvement in mental health out-
comes, (iii) studies provided rich information about
the components of psychosocial interventions, (iv)
Importantly, these studies showed that psychosocial
interventions can address both mental health prob-
lems and adherence with Anti-Tuberculosis treatment
(ATT), the two most significant barriers in TB control
worldwide.
In view of the fact that meta-analysis could not be
done, it is not possible to provide quantitative esti-
mates of any intervention, however the narrative
review of the studies provides useful insights into the
development of interventions and elements of inter-
ventions that can be used in future scale up. The
psychosocial interventions addressing CMD need to
focus on stigma, socioeconomic disadvantage, guilt of
making family members vulnerable, fear of conta-
gion, health belief models, developing self-efficacy
and support for family members. Therapies will need
a broad transdiagnostic focus, and therapeutic
approaches such as Cognitive Behavioural Therapy
and Acceptance and Commitment Therapy could pro-
vide theoretical underpinning for future interventions.
The evidence suggests that task shifting involving TB
health workers, using a transdiagnostic and stepped
care approach can be helpful in implementing
psychological intervention programme in TB control
programmes, in line with literature on scaling up psy-
chosocial interventions in LMIC.37,38 A stepped
model consisting of detecting CMD using a simple
screening questionnaire, and providing care for those
with emotional problems,27 appeared to be an
effective approach that could be used for scaling up
interventions.
Pharmacological treatment of TB in depression is
particularly challenging in view of significant inter-
actions between ATT and antidepressants.39 Potential
interactions include therapeutic failure or toxicity of
ATT and/or psychoactive agents and concerns have
been raised over the potential for drug interactions
between various SSRIs and isoniazid.39 Therefore, it
is important to examine the efficacy and safety of
antidepressants in this population, however only one
trial evaluated effect of an antidepressant. One good
quality study did not show effectiveness of Vitamin
D in TB and depression. Using pharmacological
agents such as Vitamin D in TB may be useful strat-
egy for treating depression in this population, as this
would avoid possible interaction. Other agents with a
potential antidepressant effect such as fatty acids or
anti-inflammatory drugs40 may potentially be useful
in this population and need to be evaluated in future
studies.
This study reflects the neglect of research needs of
problems facing the LMIC population. In 2018, the 30
high TB burden countries were mostly LMIC and
these accounted for 87% of new TB cases worldwide.
The significant association between depression and
TB and its deleterious effect on TB control has been
highlighted by number of studies.7,9 TB and depres-
sion comorbidity is now described as ‘TB-depression
syndemic’7 which poses significant risk to the Global
End TB Strategy.9 Only 13 studies describing both
pharmacological and psychosocial interventions
to tackle this huge public health problem is a sad
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reflection of the priorities for research on public
health problems faced by LMIC.
Strengths and limitations
We used a robust methodology following PRISMA
guidelines and a comprehensive search strategy that
captured all relevant studies on the subject. Only one
potentially eligible study could not be included as the
full text was in Chinese language.41 The information
available in the abstract (quasi experimental with 74
participants) of the study showed that this study would
not materially change the findings of our review.
The major limitations of this review are that
included studies were mostly of low quality, had
poorly reported mental health outcomes. We only
included English language studies and may have
missed studies published in other languages. Publica-
tion bias arising from the fact that studies with nega-
tive results are less likely to be published may also
have affected results.
Almost all controlled trials had high or unclear risk
of bias. The observational studies lacked proper con-
trol groups and adequate description of participants
and outcomes. Despite these limitations, we believe
we have identified major components of potentially
successful interventions and diagnostic and screening
measures that can help to design future studies. We
also identify major barriers in implementing these
interventions in LMIC that can help in scaling up the
interventions for CMD in TB.
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